Tag Archives: Eli Lilly
By Ben Comer | Published: October 17, 2012
FDA’s head of neurology products told industry execs at the Prix Galien Forum that the agency is open to alternative clinical trial designs in Alzheimer’s disease, and would like to see more combination products in clinical testing.
By Clark Herman | Published: October 12, 2012
With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By Ben Comer | Published: December 7, 2011
Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.